Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
- Pivot to U.S.-based Supply Chain for Critical Input Materials Completed -
STONY BROOK, NY / ACCESS Newswire / April 21, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the 'Company'), a leader in PCR-based DNA technologies, today announced that LineaRx, Inc., the Company's majority-owned subsidiary, has completed a long-term initiative to source critical input materials for its LineaDNA™ and LineaIVT™ platforms from U.S.-based suppliers. The initiative, undertaken in response to the 2024 BIOSECURE Act and customer demand for a U.S.-based supply chain, comes as the biopharmaceutical industry increasingly considers reshoring manufacturing operations to the U.S. in response to potential tariff impacts and to ensure a stable supply chain.
'With the completion of our supply chain pivot, the LineaDNA platform is now engineered for speed, scale, and domestic sourcing. Localized production of our DNA template materials and manufacturing enzymes enables us to better position LineaRx as a trusted and reliable manufacturing partner for developing and producing genetic medicines,' stated Clay D. Shorrock, president of LineaRx. 'As the largest PCR-based cell-free DNA producer in the United States and with capabilities further enhanced by the recent launch of GMP manufacturing services, we believe we are well-positioned to support increased domestic development and manufacturing of a wide range of genetic medicines, ranging from mRNA/DNA products to cell and gene therapies.'
LineaRx utilizes its proprietary PCR-based LineaDNA™ platform to rapidly manufacture high-fidelity, cell-free DNA used in the development and manufacture of genetic medicines in quantities ranging from milligram to multi-gram scale. By leveraging its PCR-based technology, which requires a minimal number of critical input materials, LineaRx has built a robust, U.S.-based supply chain inclusive of DNA template materials and manufacturing enzymes that represent over 75% of its manufacturing cost of goods. Previously, in June 2024, LineaRx concluded manufacturing scale-up for its proprietary RNA polymerase (LineaRNAPTM) with a U.S.-based manufacturer.
About the LineaDNA™ and LineaIVT™ Platforms
The LineaDNA platform is an entirely cell-free DNA production platform founded on Applied DNA's long-standing expertise in the large-scale enzymatic production of DNA. Capable of producing DNA in quantities ranging from milligrams to grams, the LineaDNA platform can produce high-fidelity DNA constructs ranging from 100bp to 20kb in size. The DNA produced via the LineaDNA platform is free of the adventitious DNA sequences found in other sources of DNA, is rapidly scalable, and provides for simple chemical modification of DNA constructs. The LineaIVT platform combines DNA IVT template manufacturing via the LineaDNA platform with a proprietary RNA polymerase, LineaRNAP™, to enable mRNA and sa-mRNA manufacturers to produce what Applied DNA believes to be better mRNA, faster, with advantages over conventional mRNA production, including: 1) the elimination of plasmid DNA as a starting material; 2) the prevention or reduction of double-stranded DNA (dsRNA) contamination; and 3) simplified mRNA production workflows.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ('DNA'). Using the polymerase chain reaction ('PCR') to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ('RNAP') for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services.
Visit adnas.com for more information. Follow us on X and LinkedIn.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be 'forward-looking' in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, the unknown future impacts of current and future tariffs and geopolitical agendas, the unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from its LineaIVT™ and or LineaDNA™ platforms, the fact that there has never been clinical trial material and/or commercial drug product produced utilizing the LineaDNA and/or Linea IVT platforms, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, its Quarterly Report on Form 10-Q filed on February 13, 2025, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Applied DNA Sciences Contact:
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, [email protected]
Web: adnas.com
###
SOURCE: Applied DNA Sciences, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
an hour ago
- Indianapolis Star
Who Will Governor DeSantis Support: Big Land Developer or Residents?
VENICE, FLORIDA / ACCESS Newswire Recent articles highlight concerns over developers increasingly utilizing special taxing districts in Florida, which can serve residents, but lately appear to be granting developers excessive control. A key example is CS/HB 4061 – West Villages Improvement District, Sarasota County. This bill, passed with expedient unanimity through the Florida Legislature, awaited being sent to the Governor for nearly two months amid Wellen Park resident protests including a petition that now has 3,177 signatures urging a veto. On its face, the bill adjusts thresholds for transitioning WVID board seats in from developer-appointed to resident-elected. Currently, the district's board has four developer-appointed and one resident-elected seat, but ongoing litigation by a few residents claims that they deserve one or two more elected seats already. CS/HB 4061 would render resident these claims moot, whether they were valid before or not. Rep. Danny Nix, the bill's sponsor, made a statement on March 26 to the House Intergovernmental Affairs Committee that putting an end to the resident litigation was an intent with the bill. Residents claim the new thresholds are unrealistic, ensuring developer control indeterminately, control including tax-billed assessment fees paid to the developer's entity for up to 100 years for holding a water permit. More alarmingly, though, the bill grants the district eminent domain powers and the ability to annex land without government approval, allowing a foreign-owned corporation's employees to force easements, seize private property, and expand the district indefinitely. CS/HB 4061 bypasses officials meant to manage growth and protect resources, enabling unsustainable development. At a June 17 12th District Court hearing, the developer's attorney suggested a 100-year water agreement is irrelevant due to impending water shortages, implying the development knowingly exceeds local resource capacity. Residents fear a for-profit, foreign-owned company will control tax assessments, profit from them, and dictate resource management and growth, leaving Floridians to bear future costs. The bill's passage raises broader concerns about developer-driven districts undermining local governance and straining resources without oversight. In 2023, DeSantis dissolved Disney's special district, Reedy Creek Improvement District, stating, ' Allowing a corporation to control its own government is bad policy, especially when the corporation makes decisions that impact an entire region… ' Unlike Reedy Creek, where Disney uses the land in perpetuity as a long-term stakeholder (for theme parks, hotels, amenities, etc.), The WVID's foreign-owned master developer makes their profit by selling off the land piece-by-piece over time. They are not a stationary, long-term stakeholder in the region. One could think that the same quote would be even more relevant. With CS/HB 4061 sent to DeSantis in the extended session's final hours, only a few days remain. Signing or ignoring the bill, which becomes law automatically if not acted upon, supports the developer. A veto is the only hope for the district's residents, with their 3,177 petitioners among 9,972 registered voters, who seek protection from unchecked corporate control. DeSantis' choice will reveal whether he prioritizes voting citizens or a foreign-owned developer's interests. Contact Information Ali Johnston Freelance Writer, Wellen Park Florida resident ali-johnston@ 941-539-5771 SOURCE: Florida resident View the original press release on ACCESS Newswire
Indianapolis Star
an hour ago
- Indianapolis Star
Arrive AI Celebrates Nasdaq Debut by Ringing Opening Bell with Early Supporters, Pioneering the Future of Autonomous Delivery
INDIANAPOLIS, INDIANA / ACCESS Newswire Arrive AI (NASDAQ:ARAI) – a pioneering autonomous delivery network anchored by Arrive Points™ – is set to mark a pivotal moment in its journey by ringing Nasdaq's opening bell on July 3, 2025. More than 300 of the company's foundational investors, alongside team members, will join the celebration, highlighting the incredible support that fueled Arrive AI's ascent to the public market. 'This isn't just about ringing a bell; it's a testament to the vision and unwavering belief of our early investors who stood with us every step of the way,' said Arrive CEO Dan O'Toole. 'This landmark achievement is for everyone who joined our journey and made this moment possible. We are the real 'we the people' story!' Arrive AI officially began publicly trading on May 15, 2025. The company is rapidly transforming the autonomous delivery landscape with its Arrive Points, intelligent, networked smart mailboxes that serve as universal access points for both traditional and autonomous deliveries. This proprietary network offers an ever-growing suite of services, ranging from real-time data tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. The system seamlessly integrates with smart home devices such as doorbells, lighting and security systems, to streamline and secure the entire last-mile delivery experience. O'Toole's journey from designing the prototype Arrive Point on a napkin to ringing the Nasdaq bell began in 2014 when he sought U.S. Patent Office protection for his smart mailbox design. In doing so, he edged out Amazon by four days and other industry leaders by weeks. He secured that foundational patent in 2017 and has continued to refine the product and has also developed an AI-driven network and platform. Arrive AI now holds eight patents for its proprietary technology. Six additional patents are pending. Arrive AI has a total of 58 patents pending for its ALM solution filed across 22 countries and has secured several trademarks. See details at The latest patent highlights the Arrive Points' cutting-edge capabilities, including: Climate control: Ensuring the integrity of sensitive deliveries, Battery charging and exchange station: Supporting the evolving needs of autonomous vehicles, Advanced safety features: A collector for identifying explosive materials and anthrax, and ultraviolet and ozone applicators to eradicate disease, viruses and harmful materials, and Comprehensive monitoring: Weather monitoring; vehicle and package tracking; facial recognition camera and software for both humans and pets; local two-way speakers; and integrated flood light and strobe LED lighting. Arrive AI is actively collaborating with leaders in the healthcare industry where efficiency, accuracy and security are paramount for deliveries. O'Toole emphasizes the platform's vast potential for data tracking and other services, solidifying its position as a universal access point for the entire autonomous logistics industry. -30- About Arrive AI: Arrive AI's patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at Media contact: Cheryl Reed at media@ Investor Relations Contact: Alliance Advisors IR at Cautionary Note Regarding Forward Looking Statements This news release and statements of Arrive AI's management in connection with this news release or related events contain or may contain 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as 'expects', 'anticipates', 'intends', 'plans', 'believes', 'potential', 'will', 'should', 'could', 'would' ,'optimistic' or 'may' and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI's public filings for more complete information, including the risk factors that may affect future results, which are available for review at Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
Business Wire
an hour ago
- Business Wire
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges
SYDNEY--(BUSINESS WIRE)--As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech's analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highlights from the report include: A growing pipeline of preclinical and Phase I–II LBP candidates, with notable concentration in Alzheimer's, IBD, diabetes, and NASH. Over 90 industry-sponsored trials launched since 2020, yet 32% have experienced discontinuation. North America and Europe leading in regulatory approvals and manufacturing activity, with rising interest from biotechs in Asia-Pacific. A projected CAGR of 38% for the LBP and microbiome CDMO market through 2030. The global market for LBPs and microbiome contract development and manufacturing organizations (CDMOs) was valued at USD 31.84 million in 2023. With growing investment in players like Vedanta Biosciences and MaaT Pharma, the LBP field is maturing but also becoming more competitive. Success will depend on smart trial design, global regulatory navigation, and efficient feasibility execution. Drawing on deep therapeutic expertise in microbiome-related studies and gastrointestinal, metabolic, and immunologic indications, Novotech supports sponsors from early development through global trial delivery. With operations spanning Asia-Pacific, North America, and Europe, Novotech is uniquely positioned to help biotech and small to mid-size pharma companies translate LBP potential into clinical success. Download the full white paper 'Why Live Biotherapeutics Matter to Emerging Biotech' here. For further information, please visit About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
